Feasibility study of alternate day oral tyerapy with TS-1 in patients with resected pancreatic cancer or biliry tract cancer
- Conditions
- pancreatic cancer or biliary tract cancer
- Registration Number
- JPRN-UMIN000014752
- Lead Sponsor
- Keio University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 75
Not provided
1) administration contraindication of TS-1 2)with recurrence before the entry of this study 3)with clinically important infection 4)with sever heart failure 5)with interstitial pneumonia or pulmonary fibrosis 6)with sever complication(Intestinal paralysis, Ileus, uncontrollable diabetes mellitus, Renal failure, Liver failure etc) 7)massive ascites fluid or pleural effusion 8)repetitive blood infusion for gastrointestinal hemorrhage or blood infusion within 14 days before accrual 9)with mental disorder receving treatment or needing treatment 10)has active carcinoma except carcinoma in situ 11) administered Flucytosine, Phenytoin, Warfarin potassium 12)pregnant women or lactating women or women who like be pregnant and willing to get pregnant, men who want his partner to be pregnant 13) doctor's decision not to be registered to this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Treatment completed rate
- Secondary Outcome Measures
Name Time Method Overall survival Relapse-free survival Adverse events Time to treatment failure